In vitro study of the NS2-3 protease of hepatitis C virus.

1997 ◽  
Vol 71 (9) ◽  
pp. 6373-6380 ◽  
Author(s):  
L Pieroni ◽  
E Santolini ◽  
C Fipaldini ◽  
L Pacini ◽  
G Migliaccio ◽  
...  
Molecules ◽  
2016 ◽  
Vol 21 (10) ◽  
pp. 1367 ◽  
Author(s):  
Shao-Ru Chen ◽  
An-Qi Wang ◽  
Li-Gen Lin ◽  
Hong-Cong Qiu ◽  
Yi-Tao Wang ◽  
...  

2019 ◽  
Vol 84 (8) ◽  
pp. 941-953 ◽  
Author(s):  
M. E. El-Houseini ◽  
A. Ismail ◽  
A. A. Abdelaal ◽  
A. H. El-Habashy ◽  
Z. F. Abdallah ◽  
...  

2004 ◽  
Vol 48 (10) ◽  
pp. 4006-4008 ◽  
Author(s):  
Jim Zhen Wu ◽  
Gary Larson ◽  
Zhi Hong

ABSTRACT An investigational nucleoside analogue drug, viramidine, has recently emerged as a potentially safer alternative to ribavirin for the treatment of hepatitis C viral infection. We have reported that viramidine mainly functions as a prodrug of ribavirin that is enriched in the liver. This in vitro study further explores viramidine's activity against nucleoside phosphorylase, a host enzyme that is responsible for phosphorolysis of ribavirin in vivo. Our experiments show that viramidine inhibits ribavirin phosphorolysis with a Ki of 2.5 μM. This result suggests that viramidine may act through a dual-action mechanism by serving as a prodrug of ribavirin and concomitantly as an inhibitor for nucleoside phosphorylase catabolism of ribavirin.


Sign in / Sign up

Export Citation Format

Share Document